|
21 Sep 2022 |
Important Milestone Reached for Evaxion Biotech’s EVX-01 Personalized Cancer Therapy
|
|
20 Sep 2022 |
Pfizer Announces Positive Top-Line Results from Phase 3 Study in 20-Valent Pneumococcal Conjugate Vaccine in Infants in the European Union
|
|
16 Sep 2022 |
Pfizer Announces Positive Top-Line Results from Phase 3 Trial of Pentavalent Meningococcal Vaccine Candidate (MenABCWY) in Adolescents
|
|
15 Sep 2022 |
Pfizer Initiates Phase 3 Study of mRNA-Based Influenza Vaccine
|
|
14 Sep 2022 |
Sabin Receives Additional $21.8 Million From BARDA to Advance Marburg Vaccine
|
|
13 Sep 2022 |
Vaxxinity Announces First Subjects Dosed in Phase 1 Clinical Trial of UB-313 for Preventive Treatment of Migraine
|
|
13 Sep 2022 |
Gritstone Presents Positive Initial Phase 2 Data in Late-Line Solid Tumor Patients Treated With KRAS-Directed Immunotherapy (SLATE) at ESMO 2022
|
|
13 Sep 2022 |
Vaxxinity Initiates Rolling Submission for UB-612 COVID-19 Vaccine with MHRA (UK)
|
|
13 Sep 2022 |
Novavax Nuvaxovid™ COVID-19 Vaccine Granted Expanded Conditional Marketing Authorization in the European Union for Use as a Booster for Adults Aged 18 and Older
|
|
13 Sep 2022 |
Dynavax Announces First Participant Dosed in a Phase 2 Clinical Trial Evaluating an Adjuvanted Plague Vaccine
|
|
13 Sep 2022 |
Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine Booster in European Union
|
|
12 Sep 2022 |
PDC*line Pharma presents first clinical results from Phase I/II trial with PDC*lung01 at ESMO 2022
|
|
09 Sep 2022 |
Genexine’s First-in-Class Therapeutic DNA Vaccine Shows Significant Potential to Extend Survival in Late-Stage Cervical Cancer
|
|
06 Sep 2022 |
CanSinoBIO's Convidecia Air™ Receives Approval in China
|
|
02 Sep 2022 |
Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron BA.1-Adapted Bivalent COVID-19 Vaccine Booster in European Union
|
|
02 Sep 2022 |
Aston Sci. Receives IND Approval from U.S. FDA for Phase 2 Clinical Trial of the Therapeutic Cancer Vaccine AST-301 in Patients with HER2 1+/2+ Breast Cancer
|
|
01 Sep 2022 |
Arcturus Announces $63.2 Million Award from the U.S. Government to Support Development of Self-amplifying mRNA Vaccine for Rapid Pandemic Influenza Response
|
|
01 Sep 2022 |
Daiichi Sankyo Announces Initiation of Phase 3 Trial of mRNA COVID-19 Vaccine (DS-5670) in Unvaccinated Individuals in Japan
|
|
31 Aug 2022 |
Moderna Receives FDA Authorization for Emergency Use of Omicron-Targeting Bivalent COVID-19 Booster Vaccine for Adults 18 Years and Older
|
|
31 Aug 2022 |
IAVI Announces First Vaccinations at Liberia Site in Phase I Clinical Trial of Lassa Fever Vaccine Candidate
|
|
31 Aug 2022 |
Pfizer and BioNTech Granted FDA Emergency Use Authorization of Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine Booster for Ages 12 Years and Older
|
|
27 Aug 2022 |
Pfizer and BioNTech Complete Submission to European Medicines Agency for Omicron BA.4/BA.5 Adapted Bivalent Vaccine
|
|
25 Aug 2022 |
Pfizer Announces Positive Top-Line Data from Phase 3 Trial of Older Adults for its Bivalent Respiratory Syncytial Virus (RSV) Vaccine Candidate
|
|
23 Aug 2022 |
Pfizer and BioNTech Submit Application to U.S. FDA for Emergency Use Authorization of Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine
|
|
19 Aug 2022 |
CureVac Starts Phase 1 Clinical Study of Modified, Omicron-Targeting COVID-19 Vaccine Candidate
|
